SpringWorks Therapeutics Reports Third Quarter 2022 : vimars

– Presented Positive Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for...

Related Keywords

Germany , Heidelberg , Baden Wüberg , Mannheim , Bernd Kasper , Malin Hultcrantz , Saqib Islam , Belantamab Mafodotin Belamaf , Linkedin , Nasdaq , Development Rd Expenses , Springworks Therapeutics Inc , Mannheim Cancer Center , European Society For Medical Oncology , University Of Heidelberg , Memorial Sloan Kettering Cancer Center , Presented Positive Data , Adult Patients , Progressing Desmoid Tumors , European Society , Medical Oncology , Expanded Global , Non Exclusive Collaboration , Continue Evaluating Nirogacestat , Belantamab Mafodotin , Multiple Myeloma , Dosed First Patient , Evaluating Nirogacestat , Ovarian Granulosa Cell Tumors , Strengthened Financial Position , Cash Equivalents , Marketable Securities , Works Therapeutics , Presidential Symposium , Chief Executive Officer , Business Highlights , B Cell Maturation Antigen , Beigene Sponsored Phase , Carlos Alb , Vice Chairman , Chief Commercial Officer , Loss Attributable , Common Stockholders , Nasdaq Swtx , Springworks Therapeutics , Nc ,